Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development

About this update from Optimi Health Corp.

Recent US executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review and expanded patient access Ibogaine is under investigation to treat PTSD, opioid use disorder and traumatic brain injury VANCOUVER, BC, June 8, 2026 /CNW/ - via IBN – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today provided an update on its recently announced Ibogaine Initiative. Optimi has secured naturally derived ibogaine from two sources, in both hydrochloride (HCl) and freebase form. Development work on the finished drug product is anticipated to commence this summer at the Company's GMP facility in British Columbia, Canada. "We are seeing a growing number of research institutions interested in ibogaine, and there is real public funding behind it now, including the $50 million program in Texas1," said Dane Stevens, CEO and Co-Founder of Optimi. "We are excited to develop and supply this product from Canada, where we have the facility, the licensing, and the experience to make it into standardized pharmaceutical dosages." Two dosage sizes, 50mg and 100mg, are planned in encapsulated format. The in-house development program covers standard operating procedures (SOPs) for finished drug encapsulation, dosage strengths, bottling, labeling, and packaging, alongside validation of the Company's manufacturing and analytical testing methods. The Company will provide an update upon completion of the program. On April 18, 2026, a U.S. Executive Order named ibogaine compounds among the psychedelic therapies prioritized for accelerated Food and Drug Administration review and expanded patient access, and directed federal funding to match state investments in psychedelic research.2 This has intensified attention on ibogaine and on the need for a reliable, GMP-grade supply. In Canada, ibogaine is not a controlled substance under Canada's Controlled Drugs and Substances Act3; rather, it is regulated under the Food and Drugs Act (Canada) and is listed on Health Canada's Prescription Drug List.4 In contrast, ibogaine remains a Schedule I substance in the United States. Combined with Optimi's GMP infrastructure and current Health Canada licensing, this reg...

View stock analysis, news, and events for Optimi Health Corp.